on April 24, 2024, medisi (688202.SH) released its 2023 annual results report.

The company achieved operating income of 1.366 billion yuan, a year-on-year decrease of 17.68, and realized net profit attributable to the parent -0.033 billion yuan, from profit to loss year-on-year, and realized net cash flow from operating activities of 33.32 million yuan, which turned positive year-on-year, and the asset-liability ratio was 23.12%, a year-on-year decrease of 8.08 percentage points.

the company's gross profit margin on sales was 23.77, down 17.02 percentage points from the same period last year, achieving basic earnings per share of -0.26 yuan, turning negative year-on-year, and the diluted return on net assets was -1.32%, turning negative year-on-year.

the company's inventory turnover rate was 6.18 times, down 1.53 times from the same period last year, and the total asset turnover rate was 0.49 times, down 0.32 times from the same period last year.

the sales cost is about 79.61 million yuan, the management cost is about 0.142 billion yuan, and the financial cost is about 4.59 million yuan.

The company's main business is preclinical research, drug discovery and pharmaceutical research, other business, housing rental business related income, material sales revenue.

the number of shareholders of the company is 10000, and the top ten shareholders of the company hold 67.01 million shares, accounting for 49.76 percent of the total share capital. the top ten shareholders are Chen jinzhang, Chen jianhuang, Chen chunlai, Wang guolin, Lin changqing, Chen guoxing, CHEN CHUN-LIN, MEDICILON INCORPORATED, the National Social Security Fund 406 portfolio, and the Bank of China Limited-Huabao China Securities Medical Trading Open Index Securities Investment Fund, the shareholding ratios were 14.15 per cent, 8.94 per cent, 5.91 per cent, 4.75 per cent, 4.06 per cent, 3.62 per cent, 3.00 per cent, 2.63 per cent, 1.45 per cent and 1.25 per cent, respectively.

the company's total research and development expenses were 0.122 billion yuan, and the proportion of research and development expenses in operating income was 8.96, up 1.55 percentage points year on year.